Mission
RegeneRaft is a UK medical device company focused on regenerative medicine that is developing novel natural tissue implants.
The lead products are:
• Breast implant for breast cancer surgery reconstruction
• Bone graft for filling bone gaps such as jawbone reconstruction following tooth loss and periodontal disease.
Background
RegeneRaft was formed as a spin-out from the Restoration of Appearance and Function Trust (RAFT), a leading UK medical research charity. RAFT was founded in 1988 by four plastic surgeons to develop wound healing therapies for severe burns.
Ten ways RAFT has changed the world
RAFT invented the world’s first therapeutic air bed to reduce pressure sore infection
Prof John Scales, inspired by the hovercraft, invented the low-loss air bed
Management Team
Dr Wang Chong
MD, MBA, Chartered MCSI
Chief Executive Officer
Dr Chong is a physician with over 30 years’ experience in the healthcare/lifesciences industry including 20 years’ experience in the financial sector. He achieved two FDA product approvals and negotiated multi-million pound out-licensing and co-marketing deals with Unilever plc and Schering-Plough Inc when he was CEO of Osmetech plc and CFO and commercial director of Phytopharm plc, UK premium LSE-listed medical device and biopharmaceutical companies respectively. He is also experienced in raising funds for and listing small to mid-cap companies in the UK and has been instrumental in raising over £70 million for small cap companies in recent years.
Dr Chong is Head of Corporate Finance at Hobart Capital Markets LLP. Prior to this he was Partner, Head of Corporate Finance and Fund Manager of New Science Fund at Shard Capital Partners LLP, Head of Lifesciences Corporate Finance at Keith Bayley Rogers & Co (a former subsidiary of the Walker Crips Group plc) and Lifesciences Analyst at Canaccord Capital Ltd. He is a former Non-Executive Director of Mediwatch plc and Lipoxen plc, AIM-listed medical diagnostic and biopharmaceutical companies respectively, where he chaired the audit and remuneration committees. He is a Chartered Member of the Chartered Institute for Securities & Investment and the Immediate Past-President of the Royal Society of Medicine’s Pharmaceutical Medicine & Research Section.
Dr Niccolò Caderni
Phd
Chairman
Dr Caderni is the Chairman of RAFT, the research institute in regenerative medicine whose scientific output is being brought to market by RegeneRaft. A former academic, subsequently with over 30 years’ experience in technology corporate finance, Dr Caderni currently holds a portfolio of non-executive positions in digital transformation and in health care. He is a Director of Unit9, a multi award-winning digital production house based in London and Los Angeles, Chairman of ETT Solutions Ltd, a company offering digital transformation to museums and cultural venues with a market leading position in Italy, and a Director of Napo Therapeutics, a pharma development and marketing company in Milan and San Francisco. He is also a Trustee of the Chelsea Academy Foundation in London, and a Partner at UCLA’s Anderson School of Management.
The recipient of an Annual Award of the Italian Physical Society for his research on General Relativity, after an academic career at the Universities of Cambridge, California and Chicago, Dr Caderni became Vice-president, Mergers and Acquisitions at Bankers Trust International in London in 1986; subsequently he was Managing Director of Phillips Son & Neale (then the third largest auction house in the world), Senior Advisor to the Bentick Thyssen family, representative on the Board of the European Policy Studies, and later Chairman of Webiz BV, the private equity arm of the Italian utility giant Enel SpA, Europe’s second largest energy provider.
Clifford Tompsett
MA, FCA
Chief Financial Officer
Mr Tompsett brings over 40 years of experience as a finance professional advising companies how to execute significant transactions and raise capital in the UK, US and Hong Kong capital markets. He was formerly Head of PricewaterhouseCooper’s UK and European Pharmaceutical and Life Sciences practice and Head of the Global IPO Centre based in London. He has worked with many of the leading global pharmaceutical companies, advising on many of the large deals in the industry, as well as many mid to small cap life science companies.
Mr Tompsett is a strategic adviser to Glycyx Therapeutics and Non-Executive Director and Chair of the Audit Committee of Reed Global Limited. He was also the Senior Independent Director and Chair of the Audit and Risk Committee of Cello Health plc, the AIM-listed global healthcare advisory company. He is a Fellow of the Institute of Chartered Accountants in England and Wales.
Elena Garcia-Gareta
PhD, MSc, BSc, BSc
Head of Research
Dr Garcia has over 17 years’ research experience in regenerative medicine, tissue engineering, biomaterials, stem cells, cell culture, and biochemistry. She was Director of Research at the RAFT Institute, Honorary Associate Professor at University College London (Division of Biomaterials and Tissue Engineering, Eastman Dental Institute) and Senior Scientist at the University of Zaragoza, leading research into tissue engineering and biomaterials science.
Dr Garcia’s research is focused on developing application-specific tissue engineering strategies that include stem cells, molecular cues and smart, biodegradable biomaterials that promote healing and aid the body’s natural tissue repair mechanisms after a traumatic injury. She is currently working on bone, skin and fat regeneration. Her main research interests are tissue-engineered constructs, composites, natural polymers, stem cells, cell/biomaterial interaction, and biomimetic in vitro/ex vivo models for biomaterial/construct characterisation and prediction of in vivo behaviour. She has published over 40 peer-reviewed articles, books and chapters, and is a co-inventor of five patents describing novel biomaterial scaffolds.